These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 35884553)

  • 1. A Prospective Study of Stereotactic Body Radiotherapy (SBRT) with Concomitant Whole-Pelvic Radiotherapy (WPRT) for High-Risk Localized Prostate Cancer Patients Using 1.5 Tesla Magnetic Resonance Guidance: The Preliminary Clinical Outcome.
    Poon DMC; Yuan J; Yang B; Wong OL; Chiu ST; Chiu G; Cheung KY; Yu SK; Yung RWH
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1.5T Magnetic Resonance-Guided Stereotactic Body Radiotherapy for Localized Prostate Cancer: Preliminary Clinical Results of Clinician- and Patient-Reported Outcomes.
    Poon DMC; Yuan J; Wong OL; Yang B; Chiu ST; Cheung KY; Chiu G; Yu SK
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole Pelvic Radiotherapy With Stereotactic Body Radiotherapy Boost vs. Conventionally Fractionated Radiotherapy for Patients With High or Very High-Risk Prostate Cancer.
    Wang SC; Ting WC; Chang YC; Yang CC; Lin LC; Ho HW; Chu SS; Lin YW
    Front Oncol; 2020; 10():814. PubMed ID: 32547949
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical Outcomes of Prostate SBRT Using Non-adaptive MR-Guided Radiotherapy.
    Sandoval ML; Rishi A; Latifi K; Grass GD; Torres-Roca J; Rosenberg SA; Yamoah K; Johnstone PAS
    Cancer Control; 2024; 31():10732748241270595. PubMed ID: 39206515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
    Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
    Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer - Acute toxicity and patient-reported outcomes in the prospective, multicenter
    Fink CA; Ristau J; Buchele C; Klüter S; Liermann J; Hoegen-Saßmannshausen P; Sandrini E; Lentz-Hommertgen A; Baumann L; Andratschke N; Baumgartl M; Li M; Reiner M; Corradini S; Hörner-Rieber J; Bonekamp D; Schlemmer HP; Belka C; Guckenberger M; Debus J; Koerber SA
    Clin Transl Radiat Oncol; 2024 May; 46():100771. PubMed ID: 38586081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year clinical outcomes of MR-guided stereotactic body radiation therapy with rectal spacer for patients with localized prostate cancer.
    Poon DMC; Yuan J; Wong OL; Yang B; Tse MY; Lau KK; Chiu ST; Chiu PK; Ng CF; Chui KL; Kwong YM; Ma WK; Cheung KY; Chiu G; Yu SK
    World J Urol; 2024 Feb; 42(1):97. PubMed ID: 38393414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of accelerated hypofractionated whole pelvis radiation therapy prior to high dose rate brachytherapy or stereotactic body radiation therapy prostate boost.
    Phuong C; Chan JW; Ni L; Wall P; Mohamad O; Wong AC; Hsu IC; Chang AJ
    Radiat Oncol; 2022 Jan; 17(1):12. PubMed ID: 35057827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR).
    Kim YJ; Ahn H; Kim CS; Kim YS
    Radiat Oncol; 2020 Oct; 15(1):234. PubMed ID: 33032643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): A randomised trial.
    Murthy V; Maitre P; Bhatia J; Kannan S; Krishnatry R; Prakash G; Bakshi G; Pal M; Menon S; Mahantshetty U
    Radiother Oncol; 2020 Apr; 145():71-80. PubMed ID: 31923712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer.
    Kim HJ; Phak JH; Kim WC
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e342-e347. PubMed ID: 26846353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive ultra-hypofractionated whole-pelvic radiotherapy in high-risk and very high-risk prostate cancer on 1.5-Tesla MR-Linac: Estimated delivered dose and early toxicity results.
    Gao L; Wei R; Qin S; Tian Y; Xia W; Song Y; Wang S; Fang H; Tang Y; Jing H; Liu Y; Tang Y; Qi S; Chen B; Li Y; Xing N; Lu N
    Chronic Dis Transl Med; 2024 Mar; 10(1):51-61. PubMed ID: 38450305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is Ultrahypofractionated Whole Pelvis Radiation Therapy (WPRT) as Well Tolerated as Conventionally Fractionated WPRT in Patients With Prostate Cancer? Early Results From the HOPE Trial.
    Mendez LC; Crook J; Martell K; Schaly B; Hoover DA; Dhar A; Velker V; Ahmad B; Lock M; Halperin R; Warner A; Bauman GS; D'Souza DP
    Int J Radiat Oncol Biol Phys; 2024 Jul; 119(3):803-812. PubMed ID: 38072323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The early result of whole pelvic radiotherapy and stereotactic body radiotherapy boost for high-risk localized prostate cancer.
    Lin YW; Lin LC; Lin KL
    Front Oncol; 2014; 4():278. PubMed ID: 25401085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
    Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
    BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer.
    Kim HJ; Phak JH; Kim WC
    Prostate Int; 2015 Dec; 3(4):118-22. PubMed ID: 26779457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
    Wolfe S; Diven MA; Marciscano AE; Zhou XK; Kishan AU; Steinberg ML; Miccio JA; Camilleri P; Nagar H
    BMC Cancer; 2023 Sep; 23(1):923. PubMed ID: 37777738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.
    Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.
    Davis J; Sharma S; Shumway R; Perry D; Bydder S; Simpson CK; D'Ambrosio D
    Cureus; 2015 Dec; 7(12):e395. PubMed ID: 26798571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.
    Chen LN; Suy S; Uhm S; Oermann EK; Ju AW; Chen V; Hanscom HN; Laing S; Kim JS; Lei S; Batipps GP; Kowalczyk K; Bandi G; Pahira J; McGeagh KG; Collins BT; Krishnan P; Dawson NA; Taylor KL; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2013 Mar; 8():58. PubMed ID: 23497695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.